Population Pharmacokinetics of Dexmedetomidine in Critically Ill Patients
Open Access
- 10 July 2013
- journal article
- research article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 33 (8) , 579-587
Abstract
Background and Objectives Although the pharmacokinetics of dexmedetomidine in healthy volunteers have been studied, there are limited data about the pharmacokinetics of long-term administration of dexmedetomidine in critically ill patients. Methods This population pharmacokinetic analysis was performed to quantify the pharmacokinetics of dexmedetomidine in critically ill patients following infusions up to 14 days in duration. The data consisted of three phase III studies (527 patients with sparse blood sampling, for a total of 2,144 samples). Covariates were included in a full random-effects covariate model and the most important covariate relationships were tested separately. The linearity of dexmedetomidine clearance was evaluated by observing steady-state plasma concentrations acquired at various infusion rates. Results The data were adequately described with a one-compartment model. The clearance of dexmedetomidine was 39 (95 % CI 37–41) L/h and volume of distribution 104 (95 % CI 93–115) L. Both clearance and volume of distribution were highly variable between patients (coefficients of variation of 62 and 57 %, respectively), which highlights the importance of dose titration by response. Covariate analysis showed a strong correlation between body weight and clearance of dexmedetomidine. The clearance of dexmedetomidine was constant in the dose range 0.2–1.4 μg/kg/h. Conclusions The pharmacokinetics of dexmedetomidine are dose-proportional in prolonged infusions when dosing rates of 0.2–1.4 μg/kg/h, recommended by the Dexdor® summary of product characteristics, are used.Keywords
This publication has 29 references indexed in Scilit:
- CYP2A6 genetic variation and dexmedetomidine dispositionEuropean Journal of Clinical Pharmacology, 2012
- Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patientsCritical Care, 2011
- A Bayesian hierarchical nonlinear mixture model in the presence of artifactual outliers in a population pharmacokinetic studyJournal of Pharmacokinetics and Pharmacodynamics, 2011
- Pharmacokinetics of dexmedetomidine in Chinese post-surgical intensive care unit patientsActa Anaesthesiologica Scandinavica, 2011
- Dexmedetomidine improves attention and recall in agitated critically ill patientsCritical Care, 2011
- Simultaneous quantitation of dexmedetomidine and glucuronide metabolites (G‐Dex‐1 and G‐Dex‐2) in human plasma utilizing liquid chromatography with tandem mass spectrometric detectionRapid Communications in Mass Spectrometry, 2004
- Bioavailability of dexmedetomidine after extravascular doses in healthy subjectsBritish Journal of Clinical Pharmacology, 2003
- Pharmacokinetic and Pharmacodynamic Considerations When Treating Patients with Sepsis and Septic ShockClinical Pharmacokinetics, 2002
- Postoperative Pharmacokinetics and Sympatholytic Effects of DexmedetomidineAnesthesia & Analgesia, 1997
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976